A Phase I randomized, investigator/participant-blind, adaptive, single ascending dose, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics, and food effects of RO7308480 following oral administration in healthy participants
Latest Information Update: 21 Jul 2022
At a glance
- Drugs RO 7308480 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Roche
Most Recent Events
- 18 Feb 2022 New trial record
- 10 Feb 2022 Status changed from recruiting to not yet recruiting.
- 10 Feb 2022 Status changed from not yet recruiting to recruiting.